Tempus AI, Inc. reported significant financial results for the first quarter of 2026, with total net revenue reaching $348.1 million, a 36% increase from $255.7 million in the same period of 2025. The growth was driven by a 35% rise in Diagnostics revenue, which totaled $261.1 million, and a 41% increase in Data and applications revenue, amounting to $87.0 million. Despite this revenue growth, the company incurred a net loss of $125.9 million, compared to a loss of $68.0 million in the prior year, reflecting increased operational costs and investments in growth.
The company's total operating expenses rose to $432.8 million, up from $324.4 million in the previous year, primarily due to higher costs associated with personnel, technology research and development, and selling, general, and administrative expenses. Notably, stock-based compensation expenses surged to $52.7 million from $23.0 million, reflecting the company's ongoing investment in talent and resources. The increase in costs was also influenced by the acquisition of Ambry Genetics, which contributed to higher personnel and operational expenses.
In terms of operational metrics, Tempus AI reported a significant increase in test volumes, with approximately 218,000 tests performed in the first quarter of 2026, up from 153,000 in the same quarter of 2025. This included a notable rise in hereditary testing volumes following the Ambry acquisition. The company also expanded its customer base, serving over 8,500 physicians and collaborating with more than 250 biotech firms, including 19 of the 20 largest public pharmaceutical companies.
Looking ahead, Tempus AI remains focused on expanding its product offerings and enhancing its technology platform. The company plans to continue investing in research and development, with a commitment to developing new assays and algorithms. Additionally, Tempus AI is optimistic about its strategic collaborations, including agreements with AstraZeneca and Pathos, which are expected to drive future revenue growth. The company believes its current cash reserves of $525.9 million, along with anticipated cash flows, will be sufficient to support its operations and growth initiatives for at least the next twelve months.
About Tempus AI, Inc.
Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.